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Genetic changes acquired during in vitro culture pose a risk for the successful application of
stem cells in regenerative medicine. To assess the genetic risks induced by culturing, we
determined all mutations in individual human stem cells by whole genome sequencing.
Individual pluripotent, intestinal, and liver stem cells accumulate 3.5 ± 0.5, 7.2 ± 1.1 and 8.3 ±
3.6 base substitutions per population doubling, respectively. The annual in vitro mutation
accumulation rate of adult stem cells is nearly 40-fold higher than the in vivo mutation
accumulation rate. Mutational signature analysis reveals that in vitro induced mutations are
caused by oxidative stress. Reducing oxygen tension in culture lowers the mutational load.
We use the mutation rates, spectra, and genomic distribution to model the accumulation of
oncogenic mutations during typical in vitro expansion, manipulation or screening experiments
using human stem cells. Our study provides empirically defined parameters to assess the
mutational risk of stem cell based therapies.
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As infinite supplies of undifferentiated and specialized cells,induced pluripotent stem cells (PSCs) and adult stem cell(ASC)-derived organoids hold great potential in regen-
erative medicine1,2. Furthermore, stem cells have become
invaluable tools in pharmacology and toxicology for in vitro
testing3–6. Maintenance of genomic integrity in culture is a pre-
requisite for the successful application of stem cells, as unwanted
mutations may influence drug responses and toxicology mea-
surements, or might lead to oncogenic transformation following
transplantation. However, multiple studies have identified
recurrent genomic alterations that originate in routinely cultured
human ASCs and PSCs7–20. Although these studies suggest that
the genomic integrity of stem cells is reduced in culture, the
majority of these studies have been performed on bulk cultures
with methods that have limited resolution. Analysis of bulk
samples poses important limitations as only mutations that are
shared among the majority of the cells are detectable. This results
in a bias toward those genomic alterations that confer a selective
advantage upon the cells, or those that occurred early in the
culturing process, while the mutational impact of the culturing
process itself and the responsible mutational mechanisms remain
as yet unclear. A better understanding of the mutational processes
that are active in culture might enable us to improve genomic
stability in culture by changing the culture conditions.
We recently established a method to accurately identify in
vivo-acquired somatic mutations in individual stem cells at base-
pair resolution by combining whole-genome sequencing (WGS)
with in vitro clonal expansion. In short, stem cells are seeded as
single cells and propagated to obtain sufficient cells for DNA
isolation and subsequent WGS. Bioinformatic analyses are per-
formed that identify with high confidence those mutations (sin-
gle-nucleotide variants, indels, copy number alterations,
structural variants (SVs), and aneuploidies) present in the original
cell and filter out germline variants and subclonal mutations that
occurred after the single-cell step21. With this method, high noise
rates of in vitro amplification approaches are avoided, which
enables the reliable detection of less than a hundred mutations
per genome22. The resultant genome-wide mutation spectra and
distribution have been shown to provide novel insights into the
activity of specific mutational and DNA repair processes in adult
stem cells in vivo and CRISPR/Cas9-edited organoids23–25.
Here, we have adapted this approach to systematically measure
the mutational impact of in vitro culture on individual cells of
three human stem cell types that were chosen for their relevance
in pharmacology, toxicology, and regenerative medicine: PSCs,
liver ASCs, and intestinal ASCs. Our study demonstrates that
in vitro culture results in increased mutation rates, and leaves a
distinct but common mutational footprint related to oxidative
stress that is independent of stem cell type. Furthermore, we
demonstrate that culturing under reduced oxygen tension
decreases the amount of mutations related to oxidative stress. We
used the measured quantitative and qualitative mutational char-
acteristics to model genome-wide mutation accumulation and
perform genetic risk assessments associated with in vitro and
in vivo applications of stem cells.
Results
Mutation accumulation in PSCs and ASCs during culture. To
investigate the mutational consequences of standard culture
conditions on the genome of stem cells in an unbiased manner,
we first established clonal human PSC and ASC lines. Clones
were established for one pluripotent embryonic stem cell line, two
induced PSC lines, two liver ASC lines, and two intestinal ASC
lines. Each clonal line was cultured for ~2–5 months (Supple-
mentary Data 1), during which mutations were allowed to
accumulate. Subsequently, a second clonal step was performed to
generate so-called subclones that were used to determine the
mutations present in the individual cells that gave rise to these
subclones. Clones, subclones, and matched nonclonal reference
samples were subjected to WGS (Fig. 1a). All germline variants
and variants that accumulated before the first clonal step were
excluded from the subclone. Variants that arose in vitro after the
second clonal step were filtered out bioinformatically based on
low variant allele frequency (VAF). This approach allowed us to
specifically measure the mutations that accumulated in the cul-
ture period in between the two clonal steps.
The total number of stem cells that is required for a particular
application, such as a cell therapy or drug study, is achieved after
a certain amount of population doublings, which is defined by the
cell division rate and the cell death rate. Thus, from a practical
perspective, knowledge on the mutation rates per population
doubling is more informative than the number of mutations per
time unit. Therefore, we determined the population-doubling
rate for all cell types under the same conditions that were also
used for the mutation accumulation experiments. We found a
population-doubling time of ~23 h for human PSCs, which
is approximately twice as fast as for the human liver and intestinal
ASCs that have population-doubling times of ~46 and ~44 h,
respectively (Fig. 1b).
The karyotypes of all clones and subclones for all three stem
cell types were analyzed by sequencing read-depth coverage, and
found to be normal without any gross chromosomal abnormal-
ities. In total, we detected 283 small insertions and deletions
(indels) in the 15 subclones (Supplementary Data 1). There was
no statistically significantly difference between the different stem
cell types in the number of indels per genome per population
doubling (ANOVA, p= 0.15, Fig. 1c). Genomic distribution
analysis revealed no effects of the indels on CDS, with the
exception of one indel in the subclone of the human embryonic
stem cell line that caused a frameshift mutation in CDKN1C.
We identified a total of 4,517 single-base-pair substitutions
(SBS) unique to the 15 subclones. Liver ASCs acquired 8.3 ± 3.6
SBS per genome per population doubling. In intestinal ASCs, the
mutation accumulation rate was similar with 7.2 ± 1.1 SBS per
genome per population doubling. The number of SBS was lower
in the PSCs than in the ASCs, with 3.5 ± 0.5 mutations per
genome per population doubling (ANOVA, p= 0.006, Fig. 1d).
For comparison with the in vivo mutation rates, we also
calculated the rate per year for both ASC types. Individual
intestinal ASCs accumulate 1415 ± 212 mutations per year, and
liver stem cells accumulate 1588 ± 679 mutations per year. These
values are nearly 40-fold higher than the in vivo mutation
accumulation rate of approximately 40 SBS per year24. These
findings demonstrate that the standard in vitro culture conditions
have a high impact on mutation accumulation rates.
SBS was significantly depleted in genic regions for all three
stem cell types (Fig. 1e). The depletion was not restricted to the
protein-coding sequence, but also included noncoding sequences,
indicating that the depletion in genic regions is mainly caused by
enhanced repair activity in genic regions and not by selection
against deleterious mutations. The depletion in coding sequences
was around 2% in all three stem cell types (Fig. 1f). In total, we
identified 19 nonsynonymous mutations across all samples, 8 in
the PSCs, 2 in the liver ASCs, and 9 in the intestinal ASCs
(Supplementary Data 2). None of the nonsynonymous mutations
affected known cancer genes based on the census of human
cancer genes26, or have previously been described to confer a
selective advantage over stem cells in culture11,19.
Mutations in promoter regions can affect gene activity and
thereby contribute to disease27,28. Mutations were depleted in the
promoter or promoter-flanking regions29 of all three stem cell
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Fig. 1 In vitro mutation accumulation in PSCs (n= 5), liver stem cells (n= 4), and intestinal stem cells (n= 6). a Schematic overview of the
experimental setup to determine in vitro-accumulated mutations in individual human PSCs, liver stem cells, and intestinal stem cells. Clonal stem cell lines
were cultured for ~2–5 months during which mutations were allowed to accumulate. At the end of the culture period, a second clonal step was performed,
and the derivative subclones were expanded until enough DNA could be isolated for WGS analysis. A biopsy or bulk culture was used as a reference
sample to determine and exclude all germline variants, which were subtracted from the clone (comparison 1) and from the subclone (comparison 2).
Finally, with these results, the clonal variants were subtracted to identify all variants that were unique to the subclone. b Growth curves for PSCs (green),
liver stem cells (red), and intestinal stem cells (blue). c Box–whisker plots showing the median, first and third quartiles, and minimum and maximum of the
number of indels per genome per population doubling (statistical test used: ANOVA). d Box–whisker plots showing the median, first and third quartiles,
and minimum and maximum of the number of SBS per genome per population doubling. Statistical test used: ANOVA. e Top panels: genomic distribution
of the observed versus the expected amount of mutations per genome per doubling. Bottom panels: log2 of the ratio between the total number of observed
mutations versus the total number of the expected amount of mutations. Asterisks denote statistically significant differences between observed and
expected (binomial test). CDS coding sequence. f Relative number of SBS per cell type (left circles) and those affecting protein-coding DNA (right circles).
Nonsynonymous SBS leads to amino-acid changes, whereas synonymous mutations do not have an effect on the protein sequence. g Top panels: genomic
distribution of the observed versus the expected amount of mutations per genome per doubling at promoter and promoter-flanking regions. Error bars
represent the standard deviation. Bottom panels: log2 of the ratio between the total number of observed versus the total number of the expected amount of
mutations at promoter and promoter-flanking regions. Asterisks denote statistically significant differences between observed and expected.
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types, particularly in the intestinal ASCs (Fig. 1g). Mutations in
heterochromatin are generally considered harmless, because the risk
that functional elements are affected is low. In all three stem cell
types, mutations were significantly enriched in heterochromatic
laminin-associated domains (LADs) (Fig. 1g), as is the case for
mutations that arise during reprogramming30. Functionally relevant
genomic regions thus appear more protected from mutation
accumulation in all three stem cell types, while heterochromatic
LADs are more susceptible to mutation accumulation.
In vitro mutation accumulation is caused by oxidative stress.
To obtain insight into the mutational processes induced by cul-
turing, we analyzed the mutation spectra of the three different
stem cell types (Fig. 2a). The in vitro mutation accumulation
spectra of liver and intestinal ASCs were significantly different
from their in vivo counterparts (Pearson’s chi-squared test; liver
ASCs: p value= 2.0e−10, intestinal ASCs: p value < 2.2e−16). The
dominant mutation type in intestinal stem cells in vivo is C > T
changes in a CpG context24, while the contribution of this
mutation type to the mutation spectrum of in vitro-cultured
intestinal ASCs was low (Fig. 2a). C > T transversions were the
predominant base substitutions in the mutational spectrum of
all three stem cell types, encompassing nearly 30% of the base
substitutions in the liver ASCs, over 35% of all the base sub-
stitutions in the intestinal ASCs, and even more than 40% of the
SBS in the PSCs (Fig. 2a). This mutation type has been linked to
reactive oxygen species (ROS)31,32. Previous studies8,33 have
demonstrated that human PSCs are susceptible to oxidative stress-
related DNA damage when cultured under atmospheric levels of
oxygen (20% O2). To further investigate the effect of oxygen levels
on mutation accumulation, we used our experimental setup
(Fig. 1a) to measure mutation accumulation in individual cells for
three different clonal PSC lines that were cultured for 3 months
under reduced oxygen tension (3% O2). In total, 532 SBS were
identified that were unique to the subclones. PSCs cultured under
reduced oxygen acquired 2.1 ± 0.3 SBS per genome per doubling,
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Fig. 2 Mutational spectrum and signature analysis. Data are derived from biological replicates. a Relative contribution of the indicated base substitution
types to the mutation spectrum. Per stem cell type, data are represented as the mean relative contribution of each mutation type over all subclones (liver
n= 4, PSC n= 5, and SI ASC n= 6). Error bars represent the standard deviation from the mean. The total number of SBS is indicated. b Box–whisker plots
showing the median, first and third quartiles, and minimum and maximum of the number of mutations per genome per population doubling under 20% and
3% O2. Statistical test used: two-sided t test. c Relative contribution of the indicated base substitution types to the mutation spectrum of individual human
pluripotent stem cell lines (n= 3) cultured for 3 months under 3% oxygen levels. Data are represented as the mean relative contribution of each mutation
type over all subclones. Error bars represent the standard deviation from the mean. The total number of SBS is indicated.
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which is a significant reduction when compared with the PSCs
that were cultured under atmospheric oxygen levels (Fig. 2b). The
mutational spectrum was also significantly different from the
spectrum of PSCs cultured under atmospheric oxygen levels
(Pearson’s chi-squared test, p value < 2.2e−16). This difference
was mainly caused by a significant reduction in the relative
number of C > T changes from around 40% to nearly 20%. This
coincided with a relative increase in the number of C–T changes,
particularly at CpG sites (Fig. 2c). Thus, culturing under reduced
oxygen tension lowers the amount of in vitro-induced mutations
that are related to oxidative stress.
Mutational signatures. To obtain more insight into the muta-
tional processes in cultured cells, we performed a de novo
extraction of mutational signatures with nonnegative matrix
factorization34, using the mutational landscapes of all samples,
including the PSC cultures under high and low-oxygen levels. We
identified three distinct signatures that were designated signatures
A–C (Fig. 3a). Signatures A and C were characterized by C > T
mutations, while signature B showed relatively more C–G and
T–C mutations and less C > T mutations. Unsupervised hier-
archical clustering of the samples based on the relative con-
tribution of the extracted signatures to the mutational profile






































































































































































































































































































Fig. 3 Mutational signature analysis. a The 96-type mutational profiles of signatures A–C extracted by nonnegative matrix factorization from the
mutational landscape of all in vitro samples. b Cosine similarity heatmap between the mutational profiles of the extracted signatures A–C and the samples.
Unsupervised hierarchical clustering of the samples based on the relative contribution of the extracted signatures to the mutational profile resulted in a
clear segregation of the samples by cell type. c Cosine similarity heatmap between the mutational profiles of the extracted signatures A–C, and the
COSMIC Signatures. e Cosine similarity heatmap between the COSMIC Signatures and the mutational profiles of the in vitro stem cell types and the
previously described in vivo ASCs24. Liver= liver stem cells in vivo, SI= intestinal stem cells in vivo, colon= colon stem cells in vivo. Unsupervised
hierarchical clustering of the samples was performed based on the cosine of the mutational profile to the COSMIC Signatures. d Cosine similarity heatmap
between COSMIC Signatures and the mutational profiles of all in vitro stem cell subclones and the previously described in vivo ASCs24. Liver= liver stem
cells in vivo, SI= intestinal stem cells in vivo, colon= colon stem cells in vivo. Unsupervised hierarchical clustering of the samples was performed based on
the cosine of the mutational profile to the COSMIC Signatures. f Relative contribution of the COSMIC Signatures to the different stem cell types.
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resulted in a clear segregation of the samples by cell type (Fig. 3b).
Signature A was enriched in the 20% O2 PSCs, signature B was
enriched in the 3% O2 PSCs and to a lesser extent in the 20% O2
PSCs, and signature C was enriched in the liver and intestinal
ASCs (Fig. 3a, b). These findings indicate that distinct mutational
processes are active in cultured ASCs, 20% O2 PSCs, and 3% O2
PSCs.
We compared the de novo signatures extracted from the in
vitro-cultured stem cells with the COSMIC signatures23. Signature
A highly resembled COSMIC Signature 18, signature B was mostly
similar to COSMIC Signature 5, and signature C mostly resembled
COSMIC Signature 8 (Fig. 3c). Next, we examined the relative
contribution of the COSMIC Signatures to the different stem cell
types. As a reference, we also included the previously described
mutational profiles of in vivo-accumulated mutations for the liver,
the small intestine, and the colon in this analysis24. Hierarchical
clustering based on similarity with the COSMIC signatures
resulted in clustering of the in vitro-cultured samples and within
that cluster grouping by stem cell type. The PSCs that were
cultured under reduced oxygen levels, were grouped together in a
separate cluster (Fig. 3d). A similar pattern was observed when the
data were aggregated per cell type, with the in vitro samples
cultured under atmospheric oxygen levels clustering together
resembling COSMIC Signatures 8 and 18 (Fig. 3e). There was also
a relatively high contribution of COSMIC Signatures 8 and 18 to
the in vitro-cultured samples, while the contribution of these
signatures was less in the cells that were cultured under 3%
oxygen, which showed increased contribution of COSMIC
Signatures 1 and 30 (Fig. 3f). While COSMIC Signature 1 has a
relatively large contribution to mutation accumulation in the
intestine in vivo, the contribution of this signature to the in vitro
mutational pattern is limited. Likewise, the contribution of
COSMIC Signature 5 to mutation accumulation in liver stem
cells is more prominent in vivo than in vitro. Together, these
findings further demonstrate that in vivo mutational processes
only play minor roles in vitro, where other mutational processes
are dominant. The in vitro-associated Signatures 8 and 18 are
characterized by a large contribution of C > T changes, and
Signature 18 has previously been linked to oxidative damage32,35.
This is in line with our observation that C > T transversions are
the dominant base substitutions in stem cells cultured under
atmospheric oxygen levels. Hence, in vitro mutation accumulation
seems to be mainly determined by culture-induced high levels of
oxidative stress, resulting in largely similar mutational patterns,
irrespective of the stem cell type, even though clustering analyses
indicate that stem cell-type specific mutational processes are also
active.
The mutational risk of in vitro culture. The in vitro mutational
processes may lead to the transplantation of cells carrying
pathogenic mutations. We therefore used the empirically defined
stem cell-specific mutation rates, mutation spectra, and genomic
distribution to model the risk of oncogenic mutations to occur
during in vitro culture. This revealed a near-linear correlation
between the cumulative number of pathogenic mutations in
oncogenes36 as a function of the number of stem cells that are
generated in vitro (Fig. 4a). In liver ASCs, there is one oncogenic
mutation per 3.5*106 cells, in intestinal ASCs, one per 1.3 × 107
cells, and in PSCs one per 2.4 × 107 cells. When 108 intestinal
ASCs are produced in vitro (a high-end estimate required for a
cellular transplantation), the chance for at least one oncogenic
mutation in the population is approximately 1. To place this
chance in perspective, we also calculated the number of oncogenic
mutations that occur in the colon in vivo. The risk for 108 in
vitro-produced intestinal ASCs is equivalent to the risk of accu-
mulating an oncogenic mutation in any stem cell in human colon
in vivo in 100 days (Fig. 4b). Because not all possible oncogenic
mutations are relevant for all three stem cell types, we also looked
at more specific mutations. For example, in human PSCs,
dominant negative P53mutations have been identified that confer
a selective advantage to the cells in culture19. Based on our
in vitro mutation accumulation results, we predict that these
mutations occur once in every ~2.0 × 109 PSCs (Fig. 4a). As
another example, we focused on the BRAFV600E oncogenic
mutation, which is found in ~10% of colorectal cancers37. In
intestinal ASCs, this mutation occurs once in every 3.1 × 1010
stem cells (Fig. 4a). The chance for having a BRAFV600E mutation
in the total cell population is 0.018, when 108 intestinal ASCs are
produced in vitro. This chance is equivalent to the probability
that a BRAFV600E mutation occurs in any colon stem cell in
112 days of adult age (Fig. 4c). Strikingly, the mutational risk for
oncogenic mutations was not lower for cells cultured under
reduced oxygen tension (Fig. 5a), even though the mutation rates
were decreased (Fig. 2b). We reasoned that differences in the
genomic distribution may form a possible explanation for this
seemingly contradictory result. Mutations are depleted in PSCs
cultured under 20% oxygen, but not in the PSCs cultured under
3% oxygen (Fig. 5b). Thus, the reduction in mutation rates under
low-oxygen tension is largely outside genic regions, thereby
having little effect on the oncogenic risk. On a cautionary note, in
the low-oxygen group, the number of mutations in the coding
sequence are rather low for genomic distribution analyses, and as
a result, the risk assessment is less accurate.
Discussion
Many studies have described genetic abnormalities in stem cells
during in vitro culture and/or derivation. These findings seem to
contrast with the observation that stem cells have a higher activity
of DNA repair pathways, and repair damaged DNA more effi-
ciently than differentiated cell types38–40. To systematically
investigate genome stability of stem cells, and quantify mutation
accumulation, we have applied WGS of PSCs and ASCs to
identify genetic aberrations that were acquired during the cul-
turing period in between two clonal steps. Some of the mutations
measured in this study may have originated from the clonal steps
and the accompanying enhanced cellular stress in the absence of
cell–cell contacts and lack of autocrine and paracrine factors. A
lengthy in vitro culture period was performed to maximize the
contribution of mutations induced by routine culturing, and to
minimize the contribution of mutations induced by the clonal
step. The validity of this approach is clear from the mutational
patterns of the cells grown under 3% and 20% oxygen. The
mutational patterns are clearly different from one another, indi-
cating minimal contribution of the mutations induced by the
clonal steps.
An important distinction between our study and previous
studies is that our approach enables to discriminate mutations
that originate in culture from those that have an in vivo origin or
arise as a result of the derivation process. For example, previously,
we discovered that, in vivo, ASCs acquire approximately 40
mutations per year24. Due to the accumulation of mutations with
age in vivo, ASCs of older individuals carry more mutations
in vitro as well. By our experimental approach, we excluded these
confounding factors, and demonstrate that the in vitro mutation
rates for ASCs are nearly 40-fold higher than in vivo. For tumor-
derived stem cells41, mutation rates could be even higher due
to pre-existing increased mutation rates in tumor cells. However,
the in vivo number should be considered in a lifelong context
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(decades) over a large population of stem cells, while the in vitro
number relates to the duration of culturing (weeks or months)
and the total number of cells required.
Our mutational signature analyses suggest that PSCs acquire
fewer SBSs, indels, and SVs per population doubling than ASCs.
This suggests that PSCs experience lower levels of DNA damage
or have higher activity of DNA repair pathways. Previous studies
have indeed demonstrated that human PSCs exhibit high activity
of DNA repair pathways, leading to enhanced capacity to repair
damaged DNA40,42. However, when taking into account the stem
cell-specific mutation rates, mutation spectra, and genomic dis-
tribution, mathematical modeling indicates that PSCs acquire
only slightly fewer oncogenic mutations than ASCs.
There is a strong correlation between the number of mutations
and the number of cells produced. As a consequence, the majority
of the mutations arise during the last population doubling, and
are therefore present at very low frequencies, but also remain
undetected in pool-based approaches. It is therefore impossible
to rule out the risk that a population of cells that are being
transplanted is devoid of any oncogenic mutation. This under-
scores the importance of accurate risk assessment. Our examples
illustrate that oncogenic mutations will inevitably arise during
culture as they do in vivo, but the risk for a specific oncogenic
mutation, such as BRAFV600E, is low. We therefore think that the
observed in vitro mutation rates should not impede their future
use in regenerative medicine. However, to avoid unnecessary
mutation accumulation, we recommend to minimize the time in
culture.
The in vitro mutation spectra of all three stem cell types are
characterized by high numbers of C > T transversions, which have
previously been linked to ROS. High ROS levels can cause oxidative
damage to guanine, resulting in the formation of 8-oxoguanine.
Incorporation of dAMP opposite 8-oxoguanine escapes exonu-
cleolytic proofreading by DNA polymerases, generating C > T
transversions during the next round of replication31. Previous stu-
dies demonstrated that human PSCs cultured under lower oxygen
tension indeed experience less DNA damage8,33. For the first time,
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Fig. 4 Modeling the oncogenic mutations in in vitro-cultured stem cells. a The number of oncogenic mutations as a function of the number of in vitro-
produced cells. b The probability of oncogenic mutations (x-axis) as a function of the number of in vitro-produced ASCs (primary y-axis,) and as a function
of years of adult life (secondary y-axis). c The probability of BRAFV600E mutations (x-axis) as a function of the number of in vitro-produced ASCs (primary
y-axis), and as a function of years of adult life (secondary y-axis).
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reducing oxygen tension leads to a genome-wide reduction in the
number of C > T changes, and a decrease in the total mutation rates.
This is a clear proof of principle that the mutational burden can be
influenced by tweaking culture conditions.
Taken together, the experimental approach of the current study
provides a suitable framework for studies on the effects of
mutagenic environmental factors during in vitro culture, and
allows for further optimization of culture conditions to eventually
reflect in vivo mutation rates, and to establish safe in human
applications of these powerful cellular tools.
Methods
Stem cell culture. All tissue culture products were from ThermoFisher Scientific,
unless stated otherwise. Integration-free human induced PSCs were established from
urinary cells using Sendai virus with ethical approval of the University Medical
Center Utrecht (the Netherlands) under study ID NL55260.041.15 15-736/M. Pri-
mary cells were collected by centrifugation of the urine of two healthy anonymous
male research participants who were not involved in this study, and who have
provided explicit informed consent for ips cell derivation and genetic characteriza-
tion43. The cell pellets were washed with PBS supplemented with antibiotics. The cell
pellets were resuspended in primary medium containing DMEM/high glucose and
Ham’s F12 nutrient mix, supplemented with 10% (vol/vol) fetal bovine serum, pen/
strep, and Renal Cell Growth Medium SingleQuots™ (Lonza) 2.5 μg ml−1 ampho-
tericin B. The cells were plated onto gelatin-coated plates and incubated at 37 °C in a
humidified atmosphere and 5% CO2. The medium was refreshed daily. Ninety-six
hours after plating, the medium was switched to renal cell growth medium sup-
plemented with the SingleQuots™. At near-confluency, the cells were split into new
gelatin-coated plates using TrypLE Express. Urinary cells were subsequently repro-
grammed by transduction with Sendai virus carrying human KLF4, OCT4, SOX2,
and C-MYC using the CytoTune™ iPS 2.0 Sendai Reprogramming Kit according to
the manufacturer’s protocol. Approximately, 10 days after transduction, individual
iPS colonies were manually picked and further expanded. The iPS cell lines and the
human embryonic stem cell line H9 were cultured in E8 medium on tissue culture
plates coated with Geltrex (ThermoFisher) or Matrigel (Corning)44. RNA-seq ana-
lysis confirmed that the iPS cells closely resembled human embryonic stem cells
(Fig. 6). Clonal steps were performed by limiting dilution of a single-cell suspension













































































Fig. 5 The effect of oxygen tension on the risk of acquiring oncogenic mutations in in vitro-cultured PSCs. a The number of oncogenic mutations as a
function of the number of in vitro-produced cells for pluripotent stem cells cultured under 20% and 3% oxygen. b Top panels: genomic distribution of the
observed versus the expected amount of mutations per genome per doubling. Bottom panels: log2 of the ratio between the total number of observed
mutations versus the total number of the expected amount of mutations. Asterisks denote statistically significant differences between observed and
expected (binomial test). CDS coding sequence.
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survival after the clonal steps of the PSCs, E8 medium was supplemented with
RevitaCell™. In between two clonal steps, the PSCs were cultured for 3 months to
accumulate mutations. After a 3-month culture, a second clonal step was performed.
The resulting clones were expanded until enough material was produced for WGS.
To filter out germline variants, we used a cell pellet from the preclonal bulk culture as
reference sample.
For ASCs, we used existing human liver and intestinal stem cell lines24,45. For
these lines, the patients’ informed consent was obtained, and the use for research
purposes was approved by the ethical committees of University Medical Center
Utrecht and Erasmus Medical Center, Rotterdam. Liver stem cell lines were
cultured in Advanced DMEM/F12 with HEPES, Glutamax, and
Penicillin–Streptomycin. This medium was further supplemented with N2, B27,
1.25 mM N-Acetylcysteine (Sigma), 10 nM gastrin (Tocris), Primocin (Invivogen),
and the following growth factors: 50 ng per ml EGF (Peprotech), 10% RSPO1-
conditioned media (homemade), 100 ng per ml FGF10 (Peprotech), 25 ng per ml
HGF (Peprotech), 10 mM Nicotinamide (Sigma), 5 µM A83.01 (Tocris), and 10 µM
FSK (Tocris). For the first 3 days after each clonal step, the medium contained 25
ng per ml Noggin (Peprotech), 30% Wnt3a-conditioned medium (homemade46),
10 µM Y27632 (Abmole), and stem cell cloning recovery solution (Stemgent).
Intestinal stem cell lines were cultured in Advanced DMEM/F12 with HEPES,
Glutamax, and Penicillin–Streptomycin. This medium was further supplemented
with 50% Wnt3a-conditioned medium, 20% R-Spondin-conditioned medium, B27,
1.25 mM N-Acetylcysteine, 10 mM Nicotinamide, Primocin, 0.5 mM A83-01, 30
mM SB202190 (Sigma), recombinant human Noggin, and 50 ng per ml
recombinant human EGF. For the first 3 days after each clonal step, the intestinal
organoid medium was supplemented with 10 µM Y27632.
To make clonal stem cell lines, organoids were enzymatically dissociated, and
the resulting single-cell suspension was FACS-sorted to remove all doublets. The
single-cell suspension was resuspended in Matrigel or BME (Pathclear) for
intestinal and liver stem cells, respectively, and plated as a limiting dilution series.
After 2–3 weeks, individual organoids were manually picked and mechanically
fragmented and plated under regular culture conditions. Clonal lines were further
cultured for another 53–146 days after which a second clonal step was performed.
The resulting subclones were expanded until enough material was available for
WGS. Per stem cell line, a blood sample of the same donor was also sequenced to
enable filtering for germline variants.
DNA/RNA isolation, library prep, and sequencing. DNA was isolated manually
using the genomic tip 20-G kit (Qiagen) or automated using the Qiasymphony
(Qiagen). From 200 ng of genomic DNA, DNA libraries were generated for Illu-
mina sequencing using standard protocols (Illumina). Libraries were sequenced
2 × 150 bp paired-end to 30× base coverage with Illumina HiSeq Xten. For RNA
sequencing, human iPS cells, ES cells, liver ASCs, and intestinal ASCs were col-
lected in Trizol and subjected to total RNA isolation with the QiaSymphony SP
using the QiaSymphony RNA kit (Qiagen, 931636). Subsequently, 50 ng of total
RNA was used to prepare mRNA-sequencing libraries using the Illumina Neoprep
TruSeq stranded mRNA library prep kit (Illumina, NP-202-1001), followed by
paired-end sequencing (2 × 75 bp) of the RNA libraries on a Nextseq500 to
>20 million reads per sample. All sequencing data have been deposited at the
European Genome-phenome Archive (http://www.ebi.ac.uk/ega/) under accession
numbers EGAS00001002955, EGAS00001000881, and EGAS00001001682.
Sequencing analysis. RNA-sequencing reads were mapped to the human refer-
ence genome GRCh37 with STAR v.2.4.2a47, and the BAM files were indexed using
Sambamba v0.5.8. Reads were counted using HTSeq-count 0.6.1p1, and read
counts were normalized using DESeq v1.28.0. Nonsupervised hierarchical clus-
tering was performed using DESeq2.0 v1.20. DNA-sequencing reads were mapped
against human reference genome GRCh37 using Burrows–Wheeler Alignment
(BWA–MEM) v0.7.5a.
To determine the callable loci region of a sample, we used the CallableLoci tool
from GATK (version 3.4.46) and considered genomic regions with a
minBaseQuality score of 10, a minMappingQuality score of 10, a minDepth of 20,
and a minDepthForLowMAPQ of 20. Next, we intersected the callable loci regions
of the bulk, clonal, and subclonal sample, and only considered SBS and indel
variants located in these regions. For each sample, all mutations were normalized to
the callable genome to determine the total number of mutations per whole genome
(Supplementary Data 1). To identify all SBSs of the clonal cultures, we used our


























Fig. 6 RNA-seq analysis of human adult and pluripotent stem cells. Heatmap and unsupervised hierarchical clustering of RNA-seq data for all genes for
human PSCs, human ES cells, human liver stem cells, and human intestinal stem cells.
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data analysis pipeline that enables the identification of somatic SBSs with a
confirmation rate of ~91%24. In short, we performed basic protocols 1–2 of the
Genome Analysis Toolkit (GATK) best-practices workflow for germline single-
nucleotide polymorphisms (SNPs) and indels in whole genomes to identify SBSs48.
We subsequently generated a catalog of high-quality in vitro-induced SBSs using a
custom Single Nucleotide Variant Filtering pipeline (SNVFI available at https://
github.com/UMCUGenetics/SNVFI). The SBS call set is further filtered on the
basis of quality parameters (base call quality >100, minimum coverage at variant
position >20, and VAF-filtering threshold of 0.321) and dbSNP v137.b3749. In
addition, positions that were found to be variable in at least three unrelated
individuals were excluded as these represent either unknown SNPs or recurring
sequencing and/or calling artifacts21. Furthermore, events with any evidence in the
reference sample (alternative depth > 0) were excluded. Clonality of the cultures
was verified by a distribution around 0.5 of the VAFs of the mutations. By filtering
against all mutations with allele frequencies below 0.3, we excluded all mutations
that arose during the culture period after the clonal steps. To identify all the
mutations that originated in the culture period in between both clonal steps, the
mutations identified in the second clonal culture were filtered for those present in
the bulk and the first clonal culture. The resulting number of SBSs was divided by
the population doublings, to obtain the point mutation rate for each stem cell type.
An ANOVA was performed to determine whether the mutation rates differ
significantly between the stem cell types, and a two-sided Student’s t test was
performed to test for significance differences in mutation rates between 20% and
3% oxygen conditions. Mutational pattern analysis was performed with the
MutationalPatterns R-package50. Seven-type mutation spectra were extracted from
the VCF files. Subsequently, the 96-type mutational profiles were generated, and
the average profile (centroid) was determined for the assessed SC types. The
COSMIC mutational signatures were downloaded from COSMIC website (https://
cancer.sanger.ac.uk/cosmic). Centroids were reconstructed with the 30 COSMIC
mutational signatures. Subsequently, signatures that contributed at least 10% to one
or more centroids were selected. Cosine similarities between samples and/or
signatures and relative contributions of signatures were calculated using
MutationalPatterns. Gene definitions for hg19 were retrieved from the University
of California, Santa Cruz (UCSC) Genome Browser as a TxDb annotation package
from Bioconductor. Epigenetic status datasets were downloaded from the
ENCODE website (https://www.encodeproject.org/) as BED files.
Functional consequences of coding mutations were identified using the
VariantAnnotation R-package. To test for enrichment and depletion of SBS within
genes, we used a one-sided binomial test with MutationalPatterns50. To assess the
presence of the mutations within genes and to predict their effect, the SBSs were
annotated using SnpEff51.
Unfiltered indel catalogs were extracted from the germline GATK calls acquired
in “Single nucleotide variants”. We only considered indels within the callable
autosomal genome of the clone, subclone, and control sample. We subsequently
excluded indels that are present in the dbSNP database to filter out known germline
variants, as well as those that are present in any other sample used in this study, to
exclude rare germline variants and somatic calling artifacts. From these, we only
considered indels with a filter “PASS” from VariantFiltration, with a GATK
genotype quality of at least 99, and those with a REF and ALT read support
between 10× and 60× in clone, subclone, and control sample (average read depth is
30×). Subsequently, we followed the same approach as with SBSs to detect the
culture-associated variants. Here, indels from the subclonal sample with any
evidence in the respective control and clonal sample (with VAF > 0.3) were filtered
out. From these, only clonal indels with a VAF support greater than 0.3 were
considered.
We extrapolated the number of indels to the human autosomal genome.
Subsequently, the number of indels was divided by the number of population
doublings, to obtain the indel mutation rate for each stem cell type. An ANOVA
was performed to determine whether indel mutation rates differ significantly
between stem cell types. Finally, we used SnpEff variant annotation to predict the
effect of the mutations on the genes51.
Modeling of in vitro mutation accumulation. To calculate population-doubling
time, we used the split ratios to calculate the number of cells we would have
obtained under maximum expansion after a culture period of 44 days. Next, we
applied
D ¼ T  ln 2ð Þ
ln Xe=Xbð Þ ; ð1Þ
where T is the incubation time in any unit, Xb is the cell number at the beginning
of the incubation time, and Xe is the cell number at the end of the incubation time.
To calculate the number of mutations in the protein-coding fraction of the genome,
we applied
M tð Þ ¼ 0:015  dp  μ  N0  2 mt=Dð Þ:G tð Þ;
where M(t) is the number of mutations at timepoint t, 0.015 is the coding fraction
of the whole genome and dp is the degree of depletion in the CDS, μ is the number
of mutations per cell cycle, N(0) is the number of initial cells, mt is the cell cycle
length, and G(t) is the number of generations at timepoint t. For ASCs, we used a
cell cycle length of ~26 h, and for PSCs, we applied a cell cycle length of ~18 h52.
We used a list of oncogenic mutations in driver genes36 to calculate the number
of mutations in the coding sequence that activate cancer driver genes. For details
on how this list was compiled, we refer to Tamborero et al.36. The probability P
that mutation types (C→ A, C→G, C→ T, T→ A, T→ C, and T→G) happen in
the genome can be derived from the mutation spectrum of the cell type. To
calculate the number of oncogenic mutations as a function of the number of cells,
we applied












where Mactive is number of mutations that activate driver genes, dp is depletion in
CDS, µ is the mutation rate, N is the number of cells, PX > Y is the chance on X > Y
mutation based on the mutation spectrum, nX > Y is the number of positions where
X > Y mutation results in oncogene activation, and L is the length of CDS.
To calculate the probability for an oncogenic mutation as a function of the
number of cells, we applied the following formula, where Z is the number of
activating mutations















To calculate the probability for an oncogenic mutation in vivo in 108 colon stem
cells as a function of the number of years (t) in adult life, we applied the following
formula:















Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The source-sequencing data underlying Fig. 1c–e and Figs. 2–4 is available at the
European Genome-phenome Archive through (http://www.ebi.ac.uk/ega/) under
accession numbers EGAS00001002955, EGAS00001000881, and EGAS00001001682. All
the other data supporting the findings of this study are available within the article and its
Supplementary information files and from the corresponding author upon reasonable
request. Publicly available data were also used from dbSNP (dbSNP v137.b37) and
ENCODE (https://www.encodeproject.org/).
Code availability
Filtered vcf files and supporting code are available at https://github.com/UMCUGenetics/
in_vitro_mutational_load. Mutational pattern analyses were performed with the
MutationalPatterns R-package, available at https://bioconductor.org/packages/3.6/bioc/
html/MutationalPatterns.html. Custom script to model driver probabilities is available at
https://github.com/bastiaanvdroest/DriverProbabilities.
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